Baicalin reduces liver cell damage in fatty liver disease by blocking inflammation-triggered cell death

Baicalin (BA) may improve hepatocyte health by reducing pyroptosis in a model of non-alcoholic steatohepatitis.

• BA improves liver cell morphology and reduces cell death in a fatty acid-induced model of non-alcoholic steatohepatitis.
• Treatment with BA leads to significant down-regulation of specific genes associated with inflammatory cell death, including NLRP3, GSDMD, and IL-1β.
• BA decreases levels of proteins linked to inflammation and cell death, which may reduce pyroptosis.
• The protective effects of BA are diminished when GSDMD is knocked down, suggesting its role in mediating BA's effects.

Simplified